Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy

Tomoo Sato, Masahiro Nagai, Osamu Watanabe, Tatsuro Misu, Norihiro Takenouchi, Ryuichi Ohkubo, Satoshi Ishihara, Yoshio Tsuboi, Masahisa Katsuno, Masanori Nakagawa, Takuya Matsushita, Yasuhiro Aso, Eiji Matsuura, Takashi Tokashiki, Akihiro Mukaino, Hiroaki Adachi, Kaoru Nakanishi, Yusuke Yamaguchi, Saaya Yamaguchi, Yoshihisa Yamano^*